(Competitive Insight/Unsplash) While GLP-1 drugs such as Wegovy and Ozempic are now being broadly championed and widely used, ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author ...

Todd Engel, a resident of Columbia, Md., is among the dozens of Americans now suing the maker of the popular diabetes and weight-loss drug Ozempic after they say the medication led to vision loss.

Ozempic blindness isn’t a real diagnosis. It’s a nickname used to describe sudden vision loss that may be linked to the weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, ...

NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) officially describes vision loss caused by reduced blood flow to the optic nerve ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare eye condition known as NAION (non-arteritic anterior ischemic optic ...

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following a recent study that suggests a link between the medications and a sudden, ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for type 2 diabetes and weight loss. Medications such as Ozempic, Wegovy, Mounjaro ...